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Abstract
Introduction: Management of subcutaneous implantable cardioverter defibrillator
(S‐ICD) patients with newly acquired pacing needs remains problematic. His bundle
pacing (HBP) allows for cardiac pacing without significant changes in the QRS
morphology. We hypothesized that HBP does not alter S‐ICD sensing and functions.
Methods: Twenty consecutive patients were implanted with a HB pacemaker. Among
them, 17 demonstrated successful His recruitment and were prospectively screened
with the automated screening tool (AST). Results of screenings performed immediately
after implant and during follow‐up, during intrinsic rhythm and while pacing from all
available pacing configurations, were compared using the AST score. Positive‐screening
tests were defined by greater than or equal to 1 positive vector.
Results: Among the 17 patients successfully implanted (male: 41%; mean age: 73),
13 presented an indication of ventricular pacing and four of cardiac resynchronization.
Absolute AST scores during both HBP (all configurations) and intrinsic rhythm were
similar (p: NS). Due to left bundle branch block correction, HBP resulted in higher
number of positive vectors (AST ≥ 100). AST scores were higher during HBP when
compared with right ventricular pacing (RVP) (primary vector: 272 [16; 648] vs 4.6 [0.8;
16.2]; P = .003; secondary vector: 569 [183; 1186] vs 1.5 [0.7; 8.3]; P < .0001; alternate
vector: 44 [2;125] vs 4.8 [0.9; 9.3]; P = .02) and resulted in a much higher number of
positive vectors. Up to 90% of the patients had a positive‐screening test during HBP.
This passing rate was higher when compared RVP (17%; P < .0001).
Conclusion: HBP restores normal intrinsic conduction and minimally modifies the
surface electrocardiograph and subcutaneous electrograms. When ventricular
Abbreviations: AST, automated screening tool; AV, auriculo‐ventricular; CRT, cardiac resynchronization therapy; DFT, defibrillation test; HB, His bundle; HBP, His bundle pacing; HPVP, high
percentage of ventricular pacing; LBBB, left bundle branch block; LP, leadless pacemaker; LVEF, left ventricular ejection fraction; RV, right ventricular; S‐EGMs, subcutaneous electrograms;
S‐ICD, subcutaneous implantable cardioverter defibrillator; TV, transvenous system; VF, ventricular fibrillation.
pacing is needed, HBP might represent an ideal pacing option for patients
implanted with a S‐ICD.
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1 | INTRODUCTION
In the field of cardiac defibrillation, the introduction of the
subcutaneous implantable cardioverter defibrillator (S‐ICD)
represents indubitably one of the most important developments
over the past decade. By leaving the heart and vasculature un-
touched, the S‐ ICD significantly reduces the risk of lead‐related
complications.1‐5 However, one of the major drawbacks of the
extra‐thoracic positioning of the ICD remains the absence
of pacing functionality. Therefore, the S‐ICD should not be
implanted in patients who present an indication of pacing or
resynchronization therapy. Moreover, nowadays, when a patient
implanted with a S‐ICD develops bradycardia related pacing
needs, explanting the S‐ICD and reimplanting a transvenous (TV)
system remains often the only therapeutic option. Despite
few case‐reports describing the combination of conventional
endovenous, epicardial, or leadless pacemakers (LPs) with the
S‐ICD, there is currently no clear recommendation for such pacing
strategies, mainly because proper S‐ICD functions rely on sub-
cutaneous electrograms (S‐EGMs) which, as precordial surface
electrocardiography, might dramatically and unpredictably
change during ventricular pacing. As S‐EGMs after pacemaker
implantation are unpredictable, preoperative screening on the
basis of the QRS amplitude and T wave is impossible and, con-
ventional pacing implantation may jeopardize S‐ICD functionality.
His bundle (HB) pacing promotes intrinsic conduction over the
conduction system of the heart and allows for cardiac pacing with
only minimal or no changes of the QRS morphology. Therefore, we
hypothesize that HB‐paced QRS vectors have higher probability
of appropriate sensing than other types of pacing.
2 | METHODS
2.1 | Population and study protocol
Over a 6 months period, 20 consecutive patients scheduled for im-
plantation of a HB pacemaker were prospectively included in present
study. All patients demonstrating successful His recruitment as
recommended by recent published criteria6 and with acceptable
thresholds (<3.5 V, pulse width 1ms) were submitted to a screening
for the implantation of a S‐ICD using the automated screening tool
(AST, Boston Scientific (BSCI)). Screenings were performed im-
mediately after pacemaker implantation and during follow‐up (after
3‐6 months) while pacing from all available pacing configurations.
S‐EGMs during HB pacing with selective, nonselective, left bundle
branch corrective, and noncorrective capture were obtained in both
unipolar and bipolar (Figure 1). Subsequently, comparisons between
each pacing modalities and intrinsic S‐EGMs were analyzed in a
qualitative manner (number of positive vectors) and in a quantitative
manner (using the AST score). On a per patient basis, a positive‐
screening test was defined by greater than or equal to 1 positive
vector. Our local ethics committee approved the study and all
patients consented to participate to the study.
2.2 | Automated screening tool score
The AST score has been established to determine mathematically
how compatible are the three available vectors (S‐EGMs) with the
S‐ICD. It depends on the amplitude of the R‐wave after filtering
(3‐40Hz), the R/T wave ratio and the baseline noise. The higher the
score, the more compatible is the tested vector with the S‐ICD and
the lower is the probability of over‐ and undersensing. Arbitrarily, the
passing score for S‐ICD screening has been set greater than or equal
to 100. To gather original AST scores, raw screening session was
recorded and exported onto a USB key. From the saved file, AST
scores are accessible in the XLM file attached to the screening
session (Figure 2).
2.3 | Statistical analysis
Continuous variables are reported as median and interquartile range
(IQR) or mean and SD. Group comparisons were performed using the
Kruskal‐Wallis or Mann‐Whitney tests. Categorical variables are
presented as counts and percentages and were compared between
groups using the Fisher's exact test. A two‐sided P value less than .05
was considered to indicate statistical significance. All analyses were
performed using the SPSS statistic software (version 25.0; IBM Corp,
Armonk, NY).
2.4 | Clinical vignettes
In addition to this series of patients, we present the clinical results
and follow‐up of two S‐ICD patients who developed ventricular
pacing needs, treated by the implantation of a HB pacemaker.
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3 | RESULTS
3.1 | Study population
Twenty consecutive patients were included in the study. Among
them, 17 (male: 41%; age: 73; IQR: 67‐82.5 years) demonstrated
successful HB recruitment according to current recommendation
with acceptable thresholds. Population characteristics are presented
in Table 1. Thirteen patients presented an indication of ventricular
pacing with an expected high percentage of ventricular pacing (HPVP
group). Four patients received a “HB optimized” CRT in lieu of a
traditional cardiac resynchronization (CRT group). In 14 patients, a
backup lead was placed either at the RV apex (n = 8/14) or onto the
high RV septum (n = 6/14). Nonselective HB capture was demon-
strated in 11 patients during unipolar HB pacing and in 10 patients
during bipolar HB pacing. A selective HB capture was obtained with
or without transition from nonselective pacing in nine patients in
both unipolar and bipolar configurations.
3.2 | Results of screening tests per vector
At baseline and during intrinsic rhythm, 70% of the patients from
the HPVP group and 67% from the CRT group had at least one
positive vector during automated screening test. Whereas, during
conventional RV pacing, only 22% of the patients from the HPVP
group and none of the CRT group had at least one positive vector.
With unipolar His bundle pacing, 88% and 100% (HPVP group) and
67% and 50% (CRT group) of the patients had more than or equal
F IGURE 1 Results of screening session. Surface‐screening ECGs directly extracted from the programmer during intrinsic rhythm,
nonselective, and selective unipolar and bipolar HB pacing. In all pacing configurations, all three vectors demonstrate a positive‐screening test.
Due to active filtering, no pacing artifact is discernible even during unipolar pacing configurations. ECG, electrocardiograph; HB, His bundle
F IGURE 2 Example of AST score. For all tested pacing
configurations and all vectors, the AST score was retrieved from the
XLM file attached to the recorded session. This example shows AST
score calculation for the secondary vector (same patient as in
Figure 1). All HB pacing configurations demonstrate positive (≥ 100)
AST scores. AST, automated screening tool; BNS, bipolar
nonselective His bundle pacing; BS, bipolar selective His bundle
pacing; NQRS, intrinsic rhythm; UNS, unipolar nonselective His
bundle pacing; US, unipolar selective His bundle pacing
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to 1 positive vector during nonselective and selective HB pacing,
respectively. Similarly, with bipolar HB pacing, 100% (HPVP group)
and 50% (CRT group) had more than or equal to 1 positive vector
during both nonselective and selective HB pacing (Table 2). On a
per vector analysis, absolute AST scores during both HB pacing
(all configurations) and sinus rhythm were statistically similar
(P‐value for all comparisons: NS). However, due to LBBB correc-
tion, HB pacing resulted in higher number of positive vectors
(AST ≥ 100). In contrast, AST scores were significantly higher
during HB pacing when compared with RV pacing (primary
vector: 272 [16; 648] vs 4.6 [0.8; 16.2]; P = .003; secondary vector:
569 [183; 1186] vs 1.5 [0.7; 8.3], P < .0001; alternate vector:
44 [2; 125] vs 4.8 [0.9; 9.3]; P = .02) and resulted in a much higher
number of positive vectors (Figure 3). Furthermore, positive
screenings during RV pacing were similarly low with both the
apical and the high septal RV positions.
3.3 | Results of screening tests per patient
On a per patient basis, up to 90% of the patients had a positive‐
screening test during HB pacing (Figure 4). This passing rate was
significantly higher when compared RV pacing (17%; P < .0001). In
the CRT group, HBP resulted in a complete correction of the LBBB in
two patients and in a partial LBBB correction in the two others. Only
the two patients displaying a complete correction of their LBBB were
positively screened for the S‐ICD. After a mean follow‐up period of
4 ± 3 months, 95% of the patients demonstrated stable thresholds
and similar AST scores. Leads were stable and none of the patients
needed backup RV pacing.
4 | CLINICAL FOLLOW ‐UP AND
DEFIBRILLATION TESTING
In addition to the 20 patients included in the present study,
two S‐ICD patients were implanted with a HB pacemaker after de-
velopment of ventricular pacing needs. The first patient (a 66‐years‐
old man, postinfarct ischemic cardiomyopathy‐LVEF: 15%) was im-
planted with a S‐ICD in primary prevention. Despite normal PR in-
terval at baseline, he developed 13 months after S‐ICD implantation,
intermittent episodes of symptomatic high degree auriculo‐
ventricular (AV) block. During HB pacemaker implantation (Figure 5),
HV interval was measured at 57millisecond and “concealed” selec-
tive HB capture was obtained with a threshold of 0.75 V/1ms in
bipolar configuration. Results of the automated vector select algo-
rithm (primary vector) remained similar during pacing and during
intrinsic sinus rhythm. Also, AST scores obtained during the various
pacing configurations (intrinsic, unipolar, bipolar with selective, and
nonselective HB capture) with both the automated screening tool
(through the programmer) and with the auto‐vector select (though
the S‐ICD) were similar and highly correlated. At 3 months follow‐up,
the ventricular pacing rate was 16%, selective HB recruitment
threshold decreased at 0.5 V/1ms and S‐ICD interrogation demon-
strated normal functions with no inappropriate therapies, no pro-
longation of the intelligent detection and no auto‐deactivation of the
SMART‐PASS algorithm. A defibrillation test (DFT) was, therefore,
performed to confirm appropriate functioning of both devices during
ventricular fibrillation (VF). The DFT was performed with the HB
pacemaker programmed in bipolar configuration with the following
TABLE 1 Population characteristics
All
patients
(N = 17)
HPVP
(N = 13)
CRT
(N = 4) P value*
Age, y 73 (16) 78 (17) 70 (12) .5
Male, % 41 38 50 1
NYHA, % .45
I‐II 88 92 75
III‐IV 12 8 25
LEVF, % 52 (26) 55 (14) 31 (8) .005
QRS duration at
baseline, ms
125 ± 29 118 ± 28 150 ± 20 .4
Paced QRS
duration, ms
107 ± 22 105 ± 23 113 ± 23 .4
QRS characteristics, % .2
LBBB 53 39 100
AVB 12 15 /
AF 18 23
SR 18 23
Note: Values are median (IQR), mean ± SD or percentage (%).
Abbreviations: AF, atrial fibrillation; AVB, auriculo‐ventricular block;
CRT, cardiac resynchronization therapy; HPVP, high percentage of
ventricular pacing; LBBB, left bundle branch block; LEVF, left ventricular
ejection fraction; NYHA, New York Heart Association; SR, sinus rhythm.
*P < .05 (Mann‐Whitney or Fisher's exact tests).
TABLE 2 Automated screening tool (AST) positive vectors comparison between HPVP and CRT indications relative to pacing modes
AST positive vectors (≥1)
SR RVP HBP unipolar HBP bipolar
Pacing indications NS S NS S
HPVP 70% 22% 88% 100% 100% 100%
CRT 67% / 67% 50% 50% 50%
Abbreviations: CRT, cardiac resynchronization therapy; HBP, His bundle pacing; HPVP, high percentage of ventricular pacing; NS, nonselective capture;
RVP, right ventricular pacing; S, selective capture; SR, sinus rhythm.
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parameters (AAI‐DDD 55/min, ventricular [HB] pacing output: 3.0 V
at 1 ms, ventricular [HB] sensing 0.6 mV). VF induction was
performed as described elsewhere7 using a brief application of a
50 Hz direct current commanded via the S‐ICD programmer. During
VF, and despite a relatively good R‐wave sensing during intrinsic
rhythm (2.1 mv), continuous HB pacing was observed due to severe
undersensing of the arrhythmia by the pacemaker. However, this
continuous pacing did not interfere with proper detection of the VF
F IGURE 3 Per vector comparisons of AST scores during various pacing configurations. For each pacing configuration, horizontal boxplots of
AST scores for all three vectors are represented. No pass or pass refers to a negative/positive‐screening test according to the AST score
(< or ≥ 100 respectively). AST, automated screening tool; HBP, His bundle pacing; NS, nonselective capture; RVP, right ventricular pacing;
S, selective capture; I, primary vector; II, secondary vector; III, alternate vector
F IGURE 4 AST positive vectors presented
at global and individual levels. First row: for
each pacing configuration and vector, the
percentage of positive‐screening test is
presented for the entire population. Second
and third row: for each pacing configuration,
the average number of positive vectors and
the percentage of positive‐screening test (≥1
or ≥2 positive vector) are presented at
individual level. AST, automated screening
tool; RVP, right ventricular pacing
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by the S‐ICD, which correctly identified the VF and successfully
terminated the arrhythmia with a 65J shock after 15 seconds.
Immediately postshock, HB pacing temporarily continued at sensor
driven rate due to appropriate detection of concomitant atrial
fibrillation during VF and commutation to DDI mode.
The second patient, a 78‐years‐old woman, was implanted in
secondary prevention (idiopathic VF) with a S‐ICD. Despite a normal
electrophysiology study done as a part of the clinical workup after
her resuscitation, she developed a complete, permanent AV block
after 4 years of follow‐up. During pacemaker implantation, non-
selective HB capture was obtained in bipolar configuration with a
threshold of 1.5 v/1 ms. Unfortunately, as this patient refused the
deep sedation protocol, no DFT was performed. At 1‐year follow‐up,
the automated selected vector remained identical (alternate vector)
without any delivered therapy.
5 | DISCUSSION
5.1 | Development of pacing needs in S‐ICD
recipients
In theory, patients with an indication of pacemaker or CRT should
not receive a S‐ICD. If absent at the time of implantation, the
likelihood of developing such a need appears low, especially
in younger patients. Nevertheless, the evaluation of this risk is
important before making the decision to implant a S‐ICD. This is
illustrated in the pooled S‐ICD study,8 where, despite a careful
selection process, three patients (0.3%) were explanted of their
S‐ICD within the first year for new pacing indications requiring a
TV device. Having pacing options for treating the rare patients
implanted with a S‐ICD who develop bradycardia related pacing
indications remains thus important.
5.2 | Review of currently available pacing options in
S‐ICD patients
There are a few case reports that examine the possible interaction
between pacemaker and S‐ICD systems. First, several authors have
described the addition of an S‐ICD in patients equipped with an
epicardial pacemaker connected to either bipolar9,10 or unipolar11
leads. A few publications also reported on the coimplantation of an
S‐ICD with a TV pacemaker.12,13 All these reports demonstrated
excellent function of both devices and no inappropriate shocks at
short‐term follow‐up. Still, a strict programming of the pacemaker
and S‐ICD was used to avoid potential oversensing of pacing arti-
facts, device cross talks, and ultimately inappropriate shocks. For
instance, the atrioventricular delay was programmed shorter than
the ventricular refractory period of the S‐ICD, the upper‐rate limit
was set lower than half of the first therapy zone, minimal thresholds
and safety margins are encouraged, auto‐threshold amplitudes were
proscribed, auto‐switch of polarity was deactivated, and manual
vector selection was performed according to screenings during both
pacing and intrinsic conduction. Remote monitoring of these pa-
tients is also suggested. Data on the feasibility and safety of com-
bining a S‐ICD and a LP are limited. Mondesert et al14 reported the
successful combined implantation of an S‐ICD with the Medtronic
Micra TPS LP. Both devices demonstrated normal function at
baseline and after a commended S‐ICD shock. Tjong et al15
demonstrated the feasibility of implanting the Abbott Nanostim LP
in combination with an S‐ICD both in sheep models and in one
human case. All these limited case‐series and case‐reports demon-
strate that a S‐ICD can potentially be used in combination with a
regular transvenous, epicardial, or LP to provide concomitant ven-
tricular pacing and ICD functions. However, given unexpected
changes of the QRS and T‐ wave morphologies while pacing, as well
as repolarization changes during native conduction resumption due
to T‐wave memory, conventional cardiac pacing may jeopardize the
correct functioning of the S‐ICD and expose the patient to an
increased risk of inappropriate therapy or inhibition.16 Moreover,
due to unexpected behavior occurring during VF, electromagnetic
interference, or after auto‐deactivation of the SMART‐PASS,
it is difficult to recommend coupling conventional pacing with the
S‐ICD at a larger scale without more formal safety assessment.
Importantly, a leadless cardiac pacemaker that can be used as an
add‐on to the existing S‐ICD, which has both VVI and ATP func-
tionality, is currently in development. However, up to date, it has
never been implanted in human and has not yet received approval
from regulatory authorities.
F IGURE 5 Combined S‐ICD and HB
pacemaker in a patient. Antero‐posterior and
lateral fluoroscopic projection illustrating
coimplantation of a His bundle pacemaker and
a S‐ICD. HB, His bundle; S‐ICD, subcutaneous
implantable cardioverter defibrillator
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5.3 | Optimal pacing option in S‐ICD patients
requiring ventricular pacing
The DAVID trial demonstrated that indiscriminate RV pacing could
be harmful in patients with standard ICD indications.17 The in-
criminated mechanism being a combination of induced dyssynchrony
and subsequent systolic dysfunction, followed by clinical heart failure
and arrhythmias. In addition, backup pacing programming has been
associated with proarrhythmic effect in 3% of ICD recipients and
considered responsible for up to 54% of all appropriate shocks.18
Accordingly, HB pacing might represent an ideal pacing option not
only because we demonstrated in the present study that it allows for
cardiac pacing with only minimal change of the S‐EGMs, but also
because by using the native conduction system, it does not desyn-
chronize the heart and, therefore, attenuate potential negative im-
pact of RV pacing. Furthermore, for the same reasons, no sudden
changes in the repolarization due to resumption of the intrinsic
conduction and memory effect are to be feared with selective HB
pacing. This is, however, not true for nonselective capture (where
change in repolarization might theoretically occur if the amount of
myocardial fusion is important) and in CRT candidates with a partial
or complete LBBB correction during HB pacing. Nevertheless, having
the same regular stable morphology during both intrinsic and the
paced rhythm guarantees a maximum safety while sensing with the
S‐ICD. If HB pacing is performed in a patient with an indication of
physiological pacing,19 our results demonstrate better AST scores
and more compatibility when compared with biventricular pacing.
This suggests that HB pacing may also solve inappropriate therapies
related to intermittent LBBB associated with QRS double counting,
T‐wave oversensing or memory T‐ waves.
5.4 | Insights from clinical cases
Importantly, we demonstrate the theoretical risk of undersensing of
VF by the HB pacemaker to be real. In such scenario, continuous
ventricular pacing during VF might delay or even inhibit S‐ICD sensing
and appropriate defibrillation. This is particularly true with unipolar
pacing configuration as the pacing artifact is much larger. In our series
of patient, careful review of the tracings obtained by the S‐ICD and/or
the programmer while pacing in unipolar configuration never revealed
inappropriate sensing of the pulse stimulus by the S‐ICD or cross talks
between both devices. Still, we strongly recommend not using the
unipolar configuration and turn the automated switch of polarity to
monitor. Also, devices should always have ventricular sensing (ADI, DDI,
and DDD modes) when concomitant SICD is used.
6 | LIMITATIONS
This study has several limitations worth noting. First, only two patients
were coimplanted with both devices. However, as acknowledged in the
Discussion section, the likelihood of ventricular pacing in patients
receiving an S‐ICDs is exceedingly rare (around 0.3%). Given the rarity
of the situation, conducting a large‐scale study might just not be fea-
sible. Secondly, none of these two patients coimplanted with an S‐ICD
and a HB pacemaker received a therapy for a spontaneous clinical
event. Therefore, we feel that longer follow‐up and larger number of
patients is required before recommending more firmly our approach.
Third, our study population consisted of patients with an indication of
ventricular pacing which might only partially represent those requiring
an S‐ICD in general. Also, permanent HB pacing can lead to different
degrees of fusion with septal pacing, which can vary depending on
output programmed. Although the passing rate of selective and non-
selective HB pacing were highly correlated in the present study
(Kappa coefficient:0.75; P = .001), the potential effect of various
degree of fusion on the AST score was not evaluated. Moreover, we
recognize that implanting a HBP in S‐ICD patient results in two
separate unique devices, both with a relatively limited longevity when
compared with one TV‐ICD system. Subjecting these patients to
repeated generator changes might increase overall morbidity. Finally,
BSCI is in process of development of a LP for such patients, which in
addition to pacing can also provide ATP therapy in near future. We
acknowledge that this latest therapeutic option might represent the
ultimate solution for these patients.
7 | CONCLUSION
His bundle pacing restores normal intrinsic conduction during pacing
and minimally modifies the surface ECG and S‐EGMs. Therefore,
when ventricular pacing is needed, HB pacing might represent an
ideal pacing option for patients already implanted with a sub-
cutaneous ICD.
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